Skip to content

Effectiveness of Cinnamon on Insulin Resistance ( ECIRCCOS ) December 1, 2019

Effectiveness of Cinnamon on Insulin Resistance and Corporate Composition of Obese Schoolchildren

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04476160
Acronym
ECIRCCOS
Enrollment
100
Registered
2020-07-17
Start date
2019-11-12
Completion date
2020-12-30
Last updated
2025-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Childhood, Insulin Resistance, Insulin Sensitivity

Brief summary

Childhood obesity is one of the most serious public health problems of the 21st century. It is considered that if there are no changes in prevention and treatment strategies there will be an increase to 70 million obese children by 2025. Of the only pharmacological treatments accepted at this age to improve insulin resistance is metformin, but it can condition gastrointestinal, muscular and hepatic adverse events. Cinnamon is an alternative therapy, which due to its high concentrations of polyphenols, improves insulin resistance by decreasing the proinflammatory environment that occurs in this group of patients, and unlike metformin with less frequent adverse events. The effectiveness of cinnamon has been demonstrated by decreasing insulin resistance in the adult population.

Detailed description

Controlled clinical trial, 100 children aged 10 to 15 years with obesity Body Mass Index (BMI\> 2 SD) will be selected. Children and parents who agree to participate will be measured anthropometry (weight, height, BMI, body fat) and Tanner stage. Once the 100 children have been selected and registered, a determination will be made after 8 hours of fasting leptin, ghrelin, insulin, lipid profile, liver function tests, creatinine and cinnamic acid. Subsequently they will be randomly assigned to a group that receives the intervention with cinnamon 3000mg / day, or placebo; Both groups will receive diet and physical activity recommendations according to the World Health Organization (WHO) guidelines. They will be followed for 16 weeks. During this period, patients will be contacted weekly to confirm the consumption of the capsules and interrogation of adverse effects such as dyspepsia, gastrointestinal disturbances and headache. They will be scheduled monthly for capsule counting and interrogation of adverse effects. At the end of the 16-week follow-up, anthropometry, fasting after 8 hours of leptin, ghrelin, insulin lipid profile, liver function tests, creatinine and cinnamic acid will be performed. Statistical analysis: Shapiro Wilk test will be applied to the variables with quantitative measurement scale to identify the type of distribution; in the case of parametric distribution, the data with averages and standard deviation will be presented, in case of presenting non-parametric distribution, medium and minimum and maximum values will be used. In the case of qualitative variables, they will be expressed with percentages and simple frequencies. Baseline characteristics will be compared between the two groups with t-Student or U-Mann Whitney according to the type of distribution of the variables. To evaluate the effect of the intervention, body fat deltas and biochemical measurements will be calculated by subtracting the final value (after 16 weeks of intervention) from the initial (baseline) value and statistical significance will be evaluated using comparisons between groups with paired t- or Wilcoxon. Covariance analysis control of confounding variables (ANCOVA) will be carried out.

Interventions

DIETARY_SUPPLEMENTCinnamon

children recipe 3 grams by day of cinnamon

Sponsors

Hospital Infantil de Mexico Federico Gomez
CollaboratorOTHER
Coordinación de Investigación en Salud, Mexico
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* obesity (BMI \> 95 percentile )

Exclusion criteria

* treatment with insulin or Metformin * genetic or endocrine obesity * routine consumption of cinnamon

Design outcomes

Primary

MeasureTime frameDescription
homeostatic model assessment (HOMA) index16 weeksresistence insulin is evaluated for fasting glucose and insulin
Appetite hormone (ghrelin [pg/ml])16 weeksChange in fasting serum ghrelin from baseline to the end of intervention
Appetite hormone (leptin [ng/ml])16 weeksChange in fasting serum leptin from baseline to the end of intervention

Secondary

MeasureTime frameDescription
Body mass index (BMI)16 weekschange in BMI from baseline to the end of intervention

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026